Dupilumab-Induced Erythrodermic Psoriasiform Dermatitis in Chronic Actinic Dermatitis: Case Report and Innovative Treatment Approach.

The off-label use of dupilumab has proven to be an effective treatment option for severe chronic actinic dermatitis (CAD). We present the first case of CAD presenting with dupilumab-induced erythrodermic psoriasiform dermatitis. A modified, spaced dupilumab dosing regimen, combined with cyclosporine, successfully managed both conditions, offering a promising strategy for managing dupilumab adverse effects while maintaining control over chronic actinic dermatitis.